Principal Scientist, Cancer Immunology

Job Description

EUGIT Therapeutics is seeking an expert in cancer immunotherapy. The successful candidate will report directly to the CEO and execute on a strategy to enhance gamma delta T cells' infiltration into and anti-tumor activity in the immunosuppressive microenvironment of solid tumors. We are seeking an individual who is passionate about developing novel therapies for solid cancers, believes in the vision of the company and is driven yet collegial.

What you will do:

Execute the research and preclinical development of gamma-delta T cell engineering programs Design and execute immunological/molecular assays to analyze novel genetic perturbations that improve T cell fitness and functionality Development and implementation of cell-based functional assays Help develop and guide experimental strategy and contribute to fund- raising What you will bring:

PhD in Immunology or related discipline with 3+ years of postdoctoral research experience and publications in cancer immunology Experience performing T cell functional assays (T and tumor cell co-cultures, T cell cytotoxicity assays, etc.) and multicolor flow cytometry (cell surface phenotyping, intracellular cytokine staining, phosphoflow) is strongly preferred Familiarity with one or more of the following is preferred: viral or non-viral T cell editing (e.g. generation of gene KO human T cells via CRISPR/Cas9), standard molecular biology assays (RNA/DNA extraction, etc.), automated liquid handling instrumentation, molecular cloning Ability to multitask as needed in a start-up environment and strong interest in cell therapy and/or immuno-oncology research Candidates must be authorized to work in the U.S Compensation and equity will be negotiated based on experience.

About EUGIT Therapeutics, Inc:

EUGIT therapeutics (whose co-founders include George Church and is funded by well known startup accelerator) is a pre-clinical stage biotechnology company with a single minded focus on pioneering a novel way to engineer anti-tumor gamma delta T cells for eradicating tumors which have highly immunosuppressive microenvironment, non-clonal antigens and low mutation burden. These include some of the most common cancers in women and men such as breast, ovarian and prostate cancers.